Our Amazing Rose gets a Beyer speed figure of 91 for winning the fifth race on Thursday at Saratoga by 7 3/4 lengths. She went the five furlongs in :57.68, or .59 seconds faster than stablemate Corfu did winning the second. Both making their career debuts for trainer Todd Pletcher, of course. Watch the replay.
Everyone knows that trainer Todd Pletcher is dominant is Saratoga juvenile races, but he’s profitable, too, in certain scenarios: His five-year win stat for first-time starters in dirt sprint maiden special weights is 32%, with an ROI of $2.57. In the same conditions, restricted to state-breds, he’s 46%, with an ROI of $3.25. “Perhaps the time to take down a Pletcher juvenile firster is in maiden special weight turf routes,” writes Dan Illman, who pulled the preceding numbers from DRF Formulator. Good luck getting a big price in any circumstance, though: The longest juvenile shot Pletcher has won at Saratoga with in the past five years is Interactif, in the 2009 With Anticipation. He was 16-1 at post time. The only other Pletcher winner with double-digit odds was Lawn Man, in a 2012 six-furlong MSW. He was 10-1 going into the gate.
What happens to all the 2-year-old maiden winners? Not long ago, Churchill had three stakes for 2-year-old colts in the spring. Now there’s only the Bashford Manor (plus the Debutante for fillies). And there’s virtually no such thing as an allowance race for 2-year-olds. How is this, with so many 2-year-olds on the grounds?
At Saratoga, the biggest East Coast summer meeting for 2-year-olds, 137 of 694 starters (19.7 percent) in 90 juvenile races raced without Lasix. The Lasix-free horses won only half as frequently as Lasix users … but other factors drove the disparity in win rate. Principally, trainer Todd Pletcher, the strongest 2-year-old trainer in New York, sent all his winners out with Lasix.
“We can talk about it the day after the race, but I can guarantee you right now,” [trainer Christophe Clement] said. “The better horse will win …”
Re: the first, Pletcher’s all-Lasix Spa baby squad is definitely one of the factors that must be taken into account looking at this summer’s Lasix-free winner stats. And for the second, that there’s no Lasix in the juvenile races tilted trainer Richard Hannon toward sending Moyglare Stud Stakes winner Sky Lantern to the Breeders’ Cup because, “[it’s] a level playing field for all of us.” It can only be for the good if trainers here and abroad perceive the Breeders’ Cup as letting the best horses shine through drug-free.
As the rubric for Eric Mitchell’s Blood-Horse column asks, what’s going on here? In his latest, Mitchell surveys the trainers of the Lasix-free juvenile starters owned by those who pledged to run their 2-year-olds without raceday drugs and finds promise in their results. He also offers some stats:
A chart on this page shows how the non-Salix horses have been performing. Between July 20 and Sept. 5, a total of 749 2-year-old races were run in the U.S. and Canada. Among the winners of those races, 660 (88.1%) ran on Salix and 89 (11.9%) did not.
Among horses that finished in the money, 87.4% raced on Salix and 12.6% ran without the medication.
Interesting. But what do the numbers mean? Very little, without knowing in which, of the 749 juvenile races surveyed, all of the starters were on Lasix (those races should be excluded from analysis*; as should, on the off-chance any such event occurred, any race in which no starter was on Lasix), or without knowing the breakdown between the total number of starters on Lasix and not on Lasix. A second chart accompanying the column, focusing on the 2012 Saratoga juvenile races, gives that information, but crucially leaves out the percentages: 20.4% of starts were Lasix-free; 11.2% of winners were.
Not to draw conclusions from the above — there are too many factors in play. As trainer Kiaran McLaughlin told Mitchell, “I just don’t win first time out.” But the numbers hint at a possible answer for the question of whether or not Lasix is performance enhancing, and what its role should be in training and racing. Another potentially illuminating angle on that question would be to look at the 2-year-old earnings for the Lasix-free owners — are their accounts depressed as a group? As compared to previous years? What’s the cost of eschewing raceday medications so long as Lasix remains legal?
A few weeks ago, Tyler Hamilton excited attention with the release of his book, “The Secret Race,” and its revelations about cycling’s doping culture:
The book is the holy grail for disillusioned cycling fans in search of answers. In a taut 268 pages, Hamilton confidently and systematically destroys any sense that there was ever any chance of cleaning up cycling in the early 2000s, revealing the sport’s powerful and elaborate doping infrastructure. He’s like a retiring magician who has decided to let the public in on the profession’s most guarded techniques.
(Before I go any further: Yes, Hamilton’s book is about illegal drug use in cycling, and Lasix is a legal drug in horse racing. I do not conflate the illegal and legal except in considering how decisions to use a drug or not may be distorted by perceptions of advantages employed by others to win.)
For Michael Shermer, the book highlights “the hidden price” of doping:
This is the real harm to those athletes who did not want to dope, who were given the choice to dope and opted out, who pulled over to the curb on the boulevard of broken dreams, stripped off their race number, and packed it in to go home, in most cases back to menial jobs or to finish high school or start college. Who are these cyclists? Tyler names a few in his book, but in most cases we have no idea who they are because they are the unseen ones, those whose potential was never realized because they never had the chance to compete cleanly against their peers.
Realizing potential is one of the arguments used to justify Lasix — stakes caliber horses who bleed abroad may be sent to the US to run, for instance, because their condition can be treated and their careers can continue. Lasix reveals these horses’ full abilities, goes the thinking; to deny them a legal treatment is to make them the unseen ones. And that’s really the question behind the raceday Lasix debate: Which horses should be unseen? Those who can run Lasix-free, or those who can’t run without Lasix?
*Credit to @o_crunk for bringing this point up via DM.
The 141 Lasix-free 2-year-olds were distributed over 71 races; only nine were post-time favorites. As a group, they accounted for 10 wins, 13 seconds and 14 thirds. With all the variables involved, it is difficult to assess the significance of these results. The sample is also a very small one. It can be said, though, that many 2-year-olds performed well without Lasix this summer at Saratoga. And that is good news for anyone who doesn’t like to think American horses can’t compete without this medication on race day.
Noted: “Bled” isn’t a chart comment on any of those races.
Another call for reorganizing the Breeders’ Cup schedule, from Steve Haskin:
How about if they keep the Juvenile Sprint on Friday, and, in fact, move all the juvenile races to Friday and promote it as “Future Friday?”
With the solid showings on this year’s Derby trail of Juvenile Turf graduates Soldat, Master of Hounds, and Willcox Inn, and the early grass success of Animal Kingdom and Brilliant Speed, the Breeders’ Cup can promo Future Friday as a potential spawning ground of Triple Crown horses …
Sure. It also creates a hook for promoting next year’s Breeders’ Cup (will we see the Juvenile or Juvenile Turf Fillies winner return in the Classic or the Filly and Mare Turf?) and another for invoking the past (last year’s Juvenile Sprint winner returns). It would add a real sense of continuity from year to year.